NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP
CollPlant Biotechnologies Ltd. CLGN
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.4M
▲ 360.4% vs FY2024
EPS · FY25
$-0.94
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-117.6%
Net margin · FY25
-484.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.4M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 485 cents on every revenue dollar this year.
Per share
USD -0.94
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-117.6%
Return on equity, FY2025
ROE
Operating margin-484.3%
Net margin-484.6%
Return on assets-77.9%
Each USD of equity lost 118 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−17.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+99.4%
−17.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.8M
total assets, end of FY2025
Total assetsUSD 10.8M
EquityUSD 6.1M
CashUSD 5.6M
Current ratio2.53×
Equity funds 56% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
Income tax $B
·
0.0
0.1
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.94
−1.45
−0.62
−1.53
0.02
−0.84
−2.23
1.43
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−117.6
−79.5
−23.2
−43.7
1.0
−134.8
−234.8
−118.0
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
30 of 30
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed